Biotech IV Monitor

LEGN — Legend Biotech Corporation

$4.1B market cap · 0 upcoming readouts tracked

Clinical trial readout dates for Legend Biotech Corporation, compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced.

Market cap$4.1B

In progress, no date published

Phase 3 (CARTITUDE-6)
Newly-diagnosed multiple myeloma (MM)
date not published
Enrollment Conclusion

Target dates already passed

These dates have elapsed; the company may have reported, or guidance may have shifted.

Phase 2 Ciltacabtagene autoleucel
Relapsed/Refractory Multiple Myeloma (R/R MM)
December 31, 2021
Ongoing

Companies working on similar indications

Discussion

No messages yet. If you follow LEGN, you can start the conversation.
Track LEGN in real time
See live implied volatility for LEGN and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on LEGN
Contact — questions or corrections about LEGN: dukeupt@gmail.com